




Name	Takuro Sakagami	
Country	JAPAN	
Organization	Kumamoto University	
Current Position	Professor	

Educational Background

- 1997 MD, Niigata University School of Medicine, JAPAN
- 2004 PhD, Niigata University Graduate School of Medicine, JAPAN

Professional Experiences

- 1997-1999 Resident in Internal Medicine, Niigata University School of Medicine, JAPAN
- 2004-2007 Clinical Fellow, Department of Respiratory Medicine, Niigata University Graduate School of Medical and Dental Sciences, JAPAN
- 2007-2010 Visiting research scientist, Department of Pulmonary Biology, Cincinnati Children's Hospital Medical Center (Dr. Bruce Trapnell lab), USA
- 2010-2014 Clinical Fellow, Division of Respiratory Medicine, Niigata University Graduate School of Medical and Dental Sciences, JAPAN
- 2014-2017 Assistant Professor, Department of Respiratory Medicine, Niigata University Graduate School of Medical and Dental Sciences, JAPAN
- 2017-2018 Lecture, Department of Respiratory Medicine, Niigata University Graduate School of Medical and Dental Sciences, JAPAN
- 2018-present Professor, Department of Respiratory Medicine, Faculty of Life Sciences, Kumamoto University, JAPAN

Professional Organizations

- 1997 Naional Board of Medical Practice Certificate
- 2004 Board certified member of Japanese Society of Internal Medicine
- 2011 Board certified member of Japanese Respiratory Society
- 2012 Board certified member of Japanese Society of Allergology



Main Scientific Publications

1. Sakagami T. Evolution of asthma treatment goals. *Respir Investig* 2023 61: 333-4
2. Anai M, Yoshida C, Izumi H, Muramoto K, Saruwatari K, Tomita Y, Ichiyasu H, Sakagami T: Successful treatment with dupilumab for mucus plugs in severe asthma. *Respirol Case Rep* 2023, 11(1):e01074
3. Anai M, Yoshida C, Ozono K, Furukawa H, Ishimaru Y, Sakata S, Saruwatari K, Muramoto K, Tomita Y, Saeki S, Ichiyasu H, Sakagami T: Successful concomitant therapy with mepolizumab and dupilumab for atypical eosinophilic granulomatosis with polyangiitis. *Allergol Int* 2022, 71(2):259-261.
4. Tomita Y, Goto Y, Sakata S, Imamura K, Minemura A, Oka K, Hayashi A, Jodai T, Akaike K, Anai M, Hamada S, Iyama S, Saruwatari K, Saeki S, Takahashi M, Ikeda T, Sakagami T. 2022. Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors. *Oncoimmunology* 11: 2081010
5. Migiyama Y, Sakata S, Iyama S, Tokunaga K, Saruwatari K, Tomita Y, Saeki S, Okamoto S, Ichiyasu H, Sakagami T. 2021. Airway Pseudomonas aeruginosa density in mechanically ventilated patients: clinical impact and relation to therapeutic efficacy of antibiotics. *Crit Care* 25: 59
6. Yoshizawa K, Aoki A, Shima K, Tanabe Y, Koya T, Hasegawa T, Kikuchi T, Sakagami T. 2020. Serum Anti-interferon-gamma Autoantibody Titer as a Potential Biomarker of Disseminated Nontuberculous Mycobacterial Infection. *J Clin Immunol* 40: 399-405
7. Tomita Y, Ikeda T, Sakata S, Saruwatari K, Sato R, Iyama S, Jodai T, Akaike K, Ishizuka S, Saeki S, Sakagami T. 2020. Association of Probiotic Clostridium butyricum Therapy with Survival and Response to Immune Checkpoint Blockade in Patients with Lung Cancer. *Cancer Immunol Res* 8: 1236-42
8. Kurokawa M, Koya T, Takeuchi H, Hayashi M, Sakagami T, Ishioka K, Gon Y, Hasegawa T, Kikuchi T. 2020. Association of upper and lower airway eosinophilic inflammation with response to omalizumab in patients with severe asthma. *J Asthma* 57: 71-8
9. Tazawa R, Ueda T, Abe M, Tatsumi K, Eda R, Kondoh S, Morimoto K, Tanaka T, Yamaguchi E, Takahashi A, Oda M, Ishii H, Izumi S, Sugiyama H, Nakagawa A, Tomii K, Suzuki M, Konno S, Ohkouchi S, Tode N, Handa T, Hirai T, Inoue Y, Arai T, Asakawa K, Sakagami T, Hashimoto A, Tanaka T, Takada T, Mikami A, Kitamura N, Nakata K. 2019. Inhaled GM-CSF for Pulmonary Alveolar Proteinosis. *N Engl J Med* 381: 923-32
10. Aoki A, Sakagami T*, Yoshizawa K, Shima K, Tanabe Y, Moro H, Aoki N, Watanabe S, Koya T, Hasegawa T, Morimoto K, Kurashima A, Hoshino Y, Trapnell BC, Kikuchi T. Clinical significance of interferon- γ neutralizing autoantibodies against disseminated nontuberculous mycobacterial disease *Clin Infect Dis*. 2018 Apr 3;66(8):1239-1245. [IF, 8.216; citation, 0]
11. Shima K, Koya T*, Tsukioka K, Sakagami T, Hasegawa T, Fukano C, Ohashi-Doi K, Watanabe S, Suzuki E, Kikuchi T, Effects of sublingual immunotherapy in a murine asthma model sensitized by intranasal administration of house dust mite extracts. *Allergol Int* 2017;66: 89-96. [IF, 3.194; citation, 4]
12. Furukawa T, Sakagami T*, Koya T, Hasegawa T, Kawakami H, Kimura Y, Hoshino Y, Sakamoto H, Shima K, Tsukioka K, Toyama M, Hayashi M, Kagamu H, Suzuki E, Narita I, Characteristics of eosinophilic and non-eosinophilic asthma during treatment with inhaled corticosteroids. *J Asthma* 2015;52: 417-22. [IF, 1.746; citation, 3]
13. Suzuki T, Arumugam P, Sakagami T, Lachmann N, Chalk C, Sallèse A, Abe S, Trapnell C, Carey B, Moritz T, Malik P, Lutzko C, Wood RE, Trapnell BC*.



-
- Pulmonary macrophage transplantation therapy.
Nature 2014;514: 450-4. [IF, 40.137; citation, 75]
14. Shima K, Sakagami T*, Tanabe Y, Aoki N, Moro H, Koya T, Kagamu H, Hasegawa T, Suzuki E, Narita I,
Novel assay to detect increased level of neutralizing anti-interferon gamma autoantibodies in non-tuberculous mycobacterial patients.
J Infect Chemother 2014;20: 52-6. [IF, 1.826; citation, 6]
15. Sakagami T*, Hasegawa T, Koya T, Furukawa T, Kawakami H, Kimura Y, Hoshino Y, Sakamoto H, Shima K, Kagamu H, Suzuki E, Narita I
Cluster analysis identifies characteristic phenotypes of asthma with accelerated lung function decline.
J Asthma 2014;51: 113-8. [IF, 1.746; citation, 11]
16. Sakagami T, Beck D, Uchida K, Suzuki T, Carey BC, Nakata K, Keller G, Wood RE, Wert SE, Ikegami M, Whitsett JA, Luisetti M, Davies S, Krischer JP, Brody A, Ryckman F, Trapnell BC*.
Patient-derived granulocyte/macrophage colony-stimulating factor autoantibodies reproduce pulmonary alveolar proteinosis in nonhuman primates.
Am J Respir Crit Care Med 2010;182: 49-61. [IF, 13.204; citation, 37]
17. Sakagami T, Uchida K, Suzuki T, Carey BC, Wood RE, Wert SE, Whitsett JA, Trapnell BC*, Luisetti M.
Human GM-CSF autoantibodies and reproduction of pulmonary alveolar proteinosis.
N Engl J Med 2009;361: 2679-81. [IF, 72.406; citation, 62]
18. Sakagami T*, Jinnai N, Nakajima T, Sekigawa T, Hasegawa T, Suzuki E, Inoue I, Gejyo F.
ADAM33 polymorphisms are associated with aspirin-intolerant asthma in the Japanese population.
J Hum Genet 2007;52: 66-72. [IF, 2.471; citation, 30]
-